1. Scrip
  2. >>Therapy Areas

New Mechanisms: Cardior’s Non-Coding RNA Therapeutic For Heart Failure

MicroRNAs Also Of Interest To Other Biotechs

 
• By John Davis

Germany’s Cardior is conducting clinical studies with an antisense oligonucleotide which inhibits a cellular microRNA believed to be involved in the pathology of heart failure, and is attracting attention from other pharma companies interested in the potential of this new mechanism of action.  

MicroRNA
A micro-RNA molecule. • Source: Shutterstock

The growing development effort into evaluating RNA as a target for novel therapeutics could lead to a novel type of therapy to treat heart failure, according to the clinical-stage German biotech, Cardior Pharmaceuticals GmbH.

Cardior has started a Phase Ib clinical study with its lead compound, CDR132L, an antisense oligonucleotide that inhibits a non-coding...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.